Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 1
1989 1
1990 1
1991 3
1992 6
1993 4
1994 7
1995 6
1996 4
1997 18
1998 11
1999 8
2000 6
2001 7
2002 6
2003 9
2004 9
2005 3
2006 4
2007 7
2008 2
2009 8
2010 6
2011 5
2012 6
2013 8
2014 4
2015 4
2016 3
2017 4
2018 5
2019 6
2020 9
2021 9
2022 9
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. Among authors: seregni e. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. Strosberg JR, et al. Among authors: seregni e. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15. Lancet Oncol. 2021. PMID: 34793718 Clinical Trial.
One Adrenal Is Worth Two-Reply.
Fiore M, Conti L, Seregni E. Fiore M, et al. Among authors: seregni e. JAMA Surg. 2022 Sep 1;157(9):859. doi: 10.1001/jamasurg.2022.2078. JAMA Surg. 2022. PMID: 35675048 No abstract available.
Redifferentiating agents in non-radioiodine avid cancer.
Seregni E, Vellani C, Castellani MR, Maccauro M, Pallotti F, Scaramellini G, Guzzo M, Greco A. Seregni E, et al. Q J Nucl Med Mol Imaging. 2009 Oct;53(5):513-9. Q J Nucl Med Mol Imaging. 2009. PMID: 19910904 Free article. Review.
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2.
Pusceddu S, Corti F, Prinzi N, Nichetti F, Ljevar S, Busico A, Cascella T, Leporati R, Oldani S, Pircher CC, Coppa J, Resi V, Milione M, Maccauro M, Miceli R, Tamborini E, Perrone F, Spreafico C, Niger M, Morano F, Pietrantonio F, Seregni E, Mariani L, Mazzaferro V, Di Liberti G, Fucà G, de Braud F, Vernieri C. Pusceddu S, et al. Among authors: seregni e. J Hematol Oncol. 2023 Dec 14;16(1):119. doi: 10.1186/s13045-023-01510-9. J Hematol Oncol. 2023. PMID: 38098114 Free PMC article. Clinical Trial.
Mucinous markers in breast cancer.
Seregni E, Botti C, Massaron S, Martinetti A, Ferrari L, Molteni SN, Bombardieri E. Seregni E, et al. Tumori. 1997 Mar-Apr;83(2):550-1. doi: 10.1177/030089169708300214. Tumori. 1997. PMID: 9226018 Review. No abstract available.
Hormonal regulation of MUC1 expression.
Seregni E, Botti C, Bajetta E, Ferrari L, Martinetti A, Nerini-Molteni S, Bombardieri E. Seregni E, et al. Int J Biol Markers. 1999 Jan-Mar;14(1):29-35. doi: 10.1177/172460089901400106. Int J Biol Markers. 1999. PMID: 10367247 Free article. Review.
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Lo Russo G, et al. Among authors: seregni e. Tumour Biol. 2016 Oct;37(10):12991-13003. doi: 10.1007/s13277-016-5258-9. Epub 2016 Jul 27. Tumour Biol. 2016. PMID: 27460087 Review.
209 results